Skip to main
AIM

AIM Stock Forecast & Price Target

AIM Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AIM ImmunoTech Inc. exhibits a positive outlook driven by consistently favorable data from various clinical studies, including significant results from its Phase 2a study demonstrating Ampligen's potential in treating metastatic colorectal cancer. In February 2024, the company further validated its position with encouraging outcomes from a Phase 2 study focused on Ampligen for post-COVID conditions. The ongoing advancements in research and development indicate strong catalysts for the stock, reflecting its potential in addressing critical medical needs for types of cancers and viral diseases.

Bears say

AIM ImmunoTech Inc. reported a net loss of $3.3 million for the latest period, resulting in an EPS of $(1.57), surpassing prior estimates and signaling underperformance relative to expectations. The company also faced liquidity and balance sheet risks, alongside significant concerns regarding the efficacy and regulatory approval of its product candidates, which further compound its financial vulnerabilities. Additionally, the broader market sentiment toward biotechnology investments, coupled with potential competition and shifting healthcare priorities, adds layers of uncertainty that detract from a favorable financial outlook for the company.

AIM has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AIM ImmunoTech Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AIM ImmunoTech Inc (AIM) Forecast

Analysts have given AIM a Strong Buy based on their latest research and market trends.

According to 1 analysts, AIM has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AIM ImmunoTech Inc (AIM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.